Mar. 30 at 8:49 PM
$BCTX
BriaCell Therapeutics Corp (BCTX -
$3.75 - Buy)
Phase 3 Survival Catalyst Nears as Balance Sheet Reset Supports Clinical Runway
Key Points
Thesis We maintain our BUY rating and
$15.00 price target on BriaCell Therapeutics because the stock still trades close to balance-sheet value and well below what we view as a reasonable risk-adjusted value for its late-stage oncology pipeline. Using the March 25, 2026 close of
$4.05 and 7.25 million common shares outstanding, BriaCell’s basic equity value is about
$29 million. The company reported
$28.99 million of working capital at January 31, 2026, so the market is still capitalizing Bria-IMT, Bria-OTS and BriaPro at only a modest implied enterprise value after adjusting for near-term liquidity. That discount still looks too severe for an active registrational oncology program.
Clinical Update The core asset remains Bria-IMT plus retifanlimab in the pivotal Phase 3 Bria-ABC study in metastatic breast cancer under FDA Fast Track designation. On December 9, 2025, the company said more than 230 patients had been screened and more than 160 enrolled, with topline timing still linked to first-half 2026 event accrual. On February 17, 2026, the independent DSMB again reported no safety concerns and recommended the study continue unchanged. That matters because BriaCell’s equity case now depends mainly on whether a funded, event-driven survival study reaches an interpretable interim readout without operational slippage.
Evidence Base We think the prior efficacy signal remains good enough to support a positive probability-weighted view, but not good enough to ignore readout risk. In the updated Phase 2 dataset using the same formulation now in Phase 3, BriaCell reported median overall survival of 15.6 months, with 52% one-year survival and 32% two-year survival, versus lower literature benchmarks for comparable heavily pretreated populations. The same filing noted that 9 of 25 patients treated since 2022 were still alive for more than 18 to 47 months, with no Bria-IMT-related discontinuations reported in that cohort. We view that as a credible signal, not proof, and we model it that way.
Financial Position The January financing materially improved near-term durability. BriaCell closed a
$30.0 million gross public offering on January 15, 2026 and reported 7.25 million common shares outstanding at January 31, 2026 after issuing 4.33 million common shares and seeing about 1.04 million pre-funded warrants exercised. For the six months ended January 31, 2026, R&D expense was
$12.74 million and net loss was
$15.58 million. The company still includes going-concern language, but the practical issue has shifted from immediate liquidity stress to how much dilution will be needed if the Phase 3 catalyst is delayed.
Risk Framework The main failure case is straightforward. If Phase 3 overall survival does not separate from physician’s choice, the equity likely falls back toward cash and residual platform value. The second risk is dilution. BriaCell had 5.37 million January 2026 warrants struck at
$6.93 and 161 thousand placement-agent warrants at
$8.39, creating meaningful overhang even though exercise would also add cash. Timing is the third risk, because slower event accrual would extend burn and reduce present value.
Summary
Our variant view is not that the market is missing the clinical uncertainty. It is that the market is assigning too little value to a funded Phase 3 survival asset that still has a constructive safety record, a meaningful earlier survival signal, and additional platform optionality behind it. We therefore maintain BUY and keep our
$15.00 price target unchanged.
